pursuant to the terms of a merger agreement , velox acquisition corp. , opgen 's wholly-owned subsidiary formed for the express purpose of effecting the merger , merged with and into advandx with advandx surviving as opgen 's wholly-owned subsidiary . opgen and advandx are collectively referred to hereinafter as the “ company . ” the company 's headquarters and principal operations are in gaithersburg , maryland . the company also has operations in copenhagen , denmark , and bogota , colombia . the company operates in one business segment . opgen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease . the company is developing molecular information products and services for global healthcare settings , helping to guide clinicians with more rapid and actionable information about life threatening infections , improve patient outcomes , and decrease the spread of infections caused by multidrug-resistant microorganisms , or mdros . the company 's proprietary dna tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections . the company 's molecular diagnostics and informatics products , product candidates and services combine its acuitas molecular diagnostics and acuitas lighthouse informatics platform for use with its proprietary , curated mdro knowledgebase . the company is working to deliver products and services , some in development , to a global network of customers and partners . the company 's molecular diagnostic tests provide rapid microbial identification and antibiotic resistance gene information . these products include its acuitas antimicrobial resistance , or amr , gene panel ( urine ) test in development for patients at risk for complicated urinary tract infections , or cuti , its acuitas amr gene panel ( isolates ) test in development for testing bacterial isolates , and its quickfish and pna fish fda-cleared and ce-marked diagnostics used to rapidly detect pathogens in positive blood cultures . each of its acuitas amr gene panel tests is available for sale for research use only , or ruo . the company 's acuitas lighthouse informatics systems are cloud-based hipaa compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics and actionable insights to help manage mdros in the hospital and patient care environment . components of the informatics systems include the acuitas lighthouse knowledgebase and the acuitas lighthouse software . the acuitas lighthouse knowledgebase is a relational database management system and a proprietary data warehouse of genomic data matched with antibiotic susceptibility information for bacterial pathogens . the acuitas lighthouse software system includes the acuitas lighthouse portal , a suite of web applications and dashboards , the acuitas lighthouse prediction engine , which is a data analysis software , and other supporting software components . the acuitas lighthouse software can be customized and made specific to a healthcare facility or collaborator , such as a pharmaceutical company . the acuitas lighthouse software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures . in july 2019 , it received an additional information , or ai , request from the fda detailing a number of questions related to the submission . at the time , questions from the fda focused on the intended use of the test including the correlation between marker detection and antibiotic resistance , the level of evidence to support resistance marker/organism claims , whole genome sequencing , or wgs , test validation and use as a comparator method , clinical performance of the test compared to wgs and further analysis of individual study results , in silico analysis to support test evaluations , further analysis of analytical study results , additional information regarding instrumentation for use with the test , and test reporting and labeling . on january 6 , 2020 , opgen filed a formal response to the fda 's july 2019 ai request . subsequently , the fda issued a second ai request on january 17 , 2020 to formalize additional questions and remaining requests for information from the earlier july 2019 ai request . the issuance of the january 2020 ai letter effectively placed the acuitas amr gene panel ( isolates ) 510 ( k ) submission on hold until opgen provided a formal response to the questions posed or a 180-day hold period ends , after which the acuitas amr gene panel ( isolates ) 510 ( k ) submission may be considered withdrawn and a second submission required . opgen is continuing to work interactively with the fda to finalize its formal response to the january 2020 ai letter to provide the required responses as well as answering additional questions that arose through this second interactive response review process . opgen is continuing to work with the fda to address additional questions that have arisen during the interactive review process . the fda shared with opgen a working plan to complete the fda 's review of 46 the acuitas amr gene panel ( isolates ) 510 ( k ) submission . however , we anticipate delays to the planned timeline as a result of the ongoing coronavirus pandemic . consequently , the anticipated timeline for the remainder of the second interactive resp onse review , and ultimately the clearance of the acuitas amr gene panel ( isolates ) diagnostic test is currently unknown , although we anticipate that the extensive review process is nearing completion . the company 's operations are subject to certain risks and uncertainties . story_separator_special_tag see additional discussion of the use of estimates relating to share-based compensation , and a discussion of management 's methodology for developing each of the assumptions used in such estimates , in note 3 to the accompanying consolidated financial statements . recent accounting pronouncements on january 1 , 2018 , the company adopted financial accounting standards board ( “ fasb ” ) accounting standards update ( “ asu ” ) 2014-09 , revenue from contracts with customers ( “ asc 606 ” ) , using the modified retrospective method . in adopting the guidance , the company applied the guidance to all contracts and used available practical expedients including assessing contracts with similar terms and conditions on a “ portfolio ” basis . the adoption of this new guidance did not have a material impact on the company 's consolidated financial statements . prior period amounts have not been adjusted in connection with the adoption of this standard . on january 1 , 2018 , the company adopted asu 2016-18 , statement of cash flows : restricted cash , using a retrospective transition method and applied to the periods presented on the condensed consolidated statements of cash flows . restricted cash includes cash and cash equivalents that is restricted through legal contracts , regulations or the company 's intention to use the cash for a specific purpose . the company 's restricted cash primarily related to funds held as collateral for letters of credit . in february 2016 , the fasb issued asu 2016-02 , leases ( topic 842 ) ( “ asc 842 ” ) , which amended the existing accounting standards for leases . the new standard requires lessees to record a right-of-use ( “ rou ” ) asset and a corresponding lease liability on the balance sheet ( with the exception of short-term leases ) , whereas under previous accounting standards , the company 's lease portfolio consisting of operating leases were not recognized on its consolidated balance sheets . the new standard required expanded disclosures regarding leasing arrangements . the new standard was effective for the company beginning january 1 , 2019. the company adopted this guidance effective january 1 , 2019 using the modified retrospective transition method and the following practical expedients : the company did not reassess if any expired or existing contracts are or contain leases . the company did not reassess the classification of any expired or existing leases . additionally , the company made ongoing accounting policy elections whereby the company ( i ) does not recognize rou assets or lease liabilities for short-term leases ( those with original terms of 12 months or less ) and ( ii ) combines lease and non-lease elements of our operating leases . upon adoption of the new guidance on january 1 , 2019 , the company recorded an operating lease right of use asset of approximately $ 2.2 million ( net of existing deferred rent ) and recognized a lease liability of approximately $ 2.5 million . prior to the adoption of asc 842 , deferred rent was recorded and amortized to the extent the total minimum rental payments allocated to the period on a straight-line basis exceeded or were less than the cash payments required . in june 2016 , the fasb issued asu no . 2016-13 , financial instruments - credit losses : measurement of credit losses on financial instruments ( `` asu 2016-13 `` ) . asu 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments , including trade receivables , as an allowance that reflects the entity 's current estimate of credit losses expected to be incurred . for available-for-sale debt securities with unrealized losses , the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model . the standard is effective for fiscal years , and interim periods within those fiscal years , beginning after december 15 , 2019 , with early adoption permitted . the company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements . 51 the company has evaluated all other issued and unadopted asus and believes the adoption of these standards will not have a material impact on its results of operations , financial position or cash flows . off-balance sheet arrangements as of december 31 , 2019 and 2018 , the company did not have any off-balance sheet arrangements . jobs act on april 5 , 2012 , the jobs act was enacted . section 107 of the jobs act provides that an “ emerging growth company ” can take advantage of the extended transition period provided in section 7 ( a ) ( 2 ) ( b ) of the securities act , for complying with new or revised accounting standards . in other words , an “ emerging growth company ” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies . the company has elected to use the extended transition period for complying with new or revised accounting standards under section 102 ( b ) ( 1 ) of the jobs act . this election allows it to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies . as a result of this election , the company 's financial statements may not be comparable to companies that comply with public company effective dates . subject to certain conditions set forth in the jobs act , as an “ emerging growth company , ” the company intends to rely on certain of these exemptions , including without limitation , ( i ) providing an auditor 's attestation report on our system of internal controls over financial reporting pursuant to section 404 ( b ) of the sarbanes-oxley

liquidity and capital resources at december 31 , 2019 , the company had cash and cash equivalents of $ 2.7 million , compared to $ 4.6 million at december 31 , 2018. the company has funded its operations primarily through external investor financing arrangements and has raised significant funds in 2019 and 2018 , including : on october 28 , 2019 , the company closed the october 2019 public offering of 2,590,170 units at $ 2.00 per unit and 2,109,830 pre-funded units at $ 1.99 per pre-funded unit . the offering raised gross proceeds of approximately $ 9.4 million and net proceeds of approximately $ 8.3 million . on march 29 , 2019 , the company closed the march 2019 public offering of 450,000 shares of its common stock at a public offering price of $ 12.00 per share . the offering raised gross proceeds of $ 5.4 million and net proceeds of approximately $ 4.8 million . 48 on october 22 , 2018 , the company closed its october 2018 public offering of 11 0 ,000 shares of its common stock at a public offering price of $ 1.45 per share . the offering raised gross proceeds of approximately $ 3.2 million and net proceeds of a pproximately $ 2.8 million .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources at december 31 , 2019 , the company had cash and cash equivalents of $ 2.7 million , compared to $ 4.6 million at december 31 , 2018. the company has funded its operations primarily through external investor financing arrangements and has raised significant funds in 2019 and 2018 , including : on october 28 , 2019 , the company closed the october 2019 public offering of 2,590,170 units at $ 2.00 per unit and 2,109,830 pre-funded units at $ 1.99 per pre-funded unit . the offering raised gross proceeds of approximately $ 9.4 million and net proceeds of approximately $ 8.3 million . on march 29 , 2019 , the company closed the march 2019 public offering of 450,000 shares of its common stock at a public offering price of $ 12.00 per share . the offering raised gross proceeds of $ 5.4 million and net proceeds of approximately $ 4.8 million . 48 on october 22 , 2018 , the company closed its october 2018 public offering of 11 0 ,000 shares of its common stock at a public offering price of $ 1.45 per share . the offering raised gross proceeds of approximately $ 3.2 million and net proceeds of a pproximately $ 2.8 million .
```    
 Suspicious Activity Report : pursuant to the terms of a merger agreement , velox acquisition corp. , opgen 's wholly-owned subsidiary formed for the express purpose of effecting the merger , merged with and into advandx with advandx surviving as opgen 's wholly-owned subsidiary . opgen and advandx are collectively referred to hereinafter as the “ company . ” the company 's headquarters and principal operations are in gaithersburg , maryland . the company also has operations in copenhagen , denmark , and bogota , colombia . the company operates in one business segment . opgen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease . the company is developing molecular information products and services for global healthcare settings , helping to guide clinicians with more rapid and actionable information about life threatening infections , improve patient outcomes , and decrease the spread of infections caused by multidrug-resistant microorganisms , or mdros . the company 's proprietary dna tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections . the company 's molecular diagnostics and informatics products , product candidates and services combine its acuitas molecular diagnostics and acuitas lighthouse informatics platform for use with its proprietary , curated mdro knowledgebase . the company is working to deliver products and services , some in development , to a global network of customers and partners . the company 's molecular diagnostic tests provide rapid microbial identification and antibiotic resistance gene information . these products include its acuitas antimicrobial resistance , or amr , gene panel ( urine ) test in development for patients at risk for complicated urinary tract infections , or cuti , its acuitas amr gene panel ( isolates ) test in development for testing bacterial isolates , and its quickfish and pna fish fda-cleared and ce-marked diagnostics used to rapidly detect pathogens in positive blood cultures . each of its acuitas amr gene panel tests is available for sale for research use only , or ruo . the company 's acuitas lighthouse informatics systems are cloud-based hipaa compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics and actionable insights to help manage mdros in the hospital and patient care environment . components of the informatics systems include the acuitas lighthouse knowledgebase and the acuitas lighthouse software . the acuitas lighthouse knowledgebase is a relational database management system and a proprietary data warehouse of genomic data matched with antibiotic susceptibility information for bacterial pathogens . the acuitas lighthouse software system includes the acuitas lighthouse portal , a suite of web applications and dashboards , the acuitas lighthouse prediction engine , which is a data analysis software , and other supporting software components . the acuitas lighthouse software can be customized and made specific to a healthcare facility or collaborator , such as a pharmaceutical company . the acuitas lighthouse software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures . in july 2019 , it received an additional information , or ai , request from the fda detailing a number of questions related to the submission . at the time , questions from the fda focused on the intended use of the test including the correlation between marker detection and antibiotic resistance , the level of evidence to support resistance marker/organism claims , whole genome sequencing , or wgs , test validation and use as a comparator method , clinical performance of the test compared to wgs and further analysis of individual study results , in silico analysis to support test evaluations , further analysis of analytical study results , additional information regarding instrumentation for use with the test , and test reporting and labeling . on january 6 , 2020 , opgen filed a formal response to the fda 's july 2019 ai request . subsequently , the fda issued a second ai request on january 17 , 2020 to formalize additional questions and remaining requests for information from the earlier july 2019 ai request . the issuance of the january 2020 ai letter effectively placed the acuitas amr gene panel ( isolates ) 510 ( k ) submission on hold until opgen provided a formal response to the questions posed or a 180-day hold period ends , after which the acuitas amr gene panel ( isolates ) 510 ( k ) submission may be considered withdrawn and a second submission required . opgen is continuing to work interactively with the fda to finalize its formal response to the january 2020 ai letter to provide the required responses as well as answering additional questions that arose through this second interactive response review process . opgen is continuing to work with the fda to address additional questions that have arisen during the interactive review process . the fda shared with opgen a working plan to complete the fda 's review of 46 the acuitas amr gene panel ( isolates ) 510 ( k ) submission . however , we anticipate delays to the planned timeline as a result of the ongoing coronavirus pandemic . consequently , the anticipated timeline for the remainder of the second interactive resp onse review , and ultimately the clearance of the acuitas amr gene panel ( isolates ) diagnostic test is currently unknown , although we anticipate that the extensive review process is nearing completion . the company 's operations are subject to certain risks and uncertainties . story_separator_special_tag see additional discussion of the use of estimates relating to share-based compensation , and a discussion of management 's methodology for developing each of the assumptions used in such estimates , in note 3 to the accompanying consolidated financial statements . recent accounting pronouncements on january 1 , 2018 , the company adopted financial accounting standards board ( “ fasb ” ) accounting standards update ( “ asu ” ) 2014-09 , revenue from contracts with customers ( “ asc 606 ” ) , using the modified retrospective method . in adopting the guidance , the company applied the guidance to all contracts and used available practical expedients including assessing contracts with similar terms and conditions on a “ portfolio ” basis . the adoption of this new guidance did not have a material impact on the company 's consolidated financial statements . prior period amounts have not been adjusted in connection with the adoption of this standard . on january 1 , 2018 , the company adopted asu 2016-18 , statement of cash flows : restricted cash , using a retrospective transition method and applied to the periods presented on the condensed consolidated statements of cash flows . restricted cash includes cash and cash equivalents that is restricted through legal contracts , regulations or the company 's intention to use the cash for a specific purpose . the company 's restricted cash primarily related to funds held as collateral for letters of credit . in february 2016 , the fasb issued asu 2016-02 , leases ( topic 842 ) ( “ asc 842 ” ) , which amended the existing accounting standards for leases . the new standard requires lessees to record a right-of-use ( “ rou ” ) asset and a corresponding lease liability on the balance sheet ( with the exception of short-term leases ) , whereas under previous accounting standards , the company 's lease portfolio consisting of operating leases were not recognized on its consolidated balance sheets . the new standard required expanded disclosures regarding leasing arrangements . the new standard was effective for the company beginning january 1 , 2019. the company adopted this guidance effective january 1 , 2019 using the modified retrospective transition method and the following practical expedients : the company did not reassess if any expired or existing contracts are or contain leases . the company did not reassess the classification of any expired or existing leases . additionally , the company made ongoing accounting policy elections whereby the company ( i ) does not recognize rou assets or lease liabilities for short-term leases ( those with original terms of 12 months or less ) and ( ii ) combines lease and non-lease elements of our operating leases . upon adoption of the new guidance on january 1 , 2019 , the company recorded an operating lease right of use asset of approximately $ 2.2 million ( net of existing deferred rent ) and recognized a lease liability of approximately $ 2.5 million . prior to the adoption of asc 842 , deferred rent was recorded and amortized to the extent the total minimum rental payments allocated to the period on a straight-line basis exceeded or were less than the cash payments required . in june 2016 , the fasb issued asu no . 2016-13 , financial instruments - credit losses : measurement of credit losses on financial instruments ( `` asu 2016-13 `` ) . asu 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments , including trade receivables , as an allowance that reflects the entity 's current estimate of credit losses expected to be incurred . for available-for-sale debt securities with unrealized losses , the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the current other-than-temporary impairment model . the standard is effective for fiscal years , and interim periods within those fiscal years , beginning after december 15 , 2019 , with early adoption permitted . the company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements . 51 the company has evaluated all other issued and unadopted asus and believes the adoption of these standards will not have a material impact on its results of operations , financial position or cash flows . off-balance sheet arrangements as of december 31 , 2019 and 2018 , the company did not have any off-balance sheet arrangements . jobs act on april 5 , 2012 , the jobs act was enacted . section 107 of the jobs act provides that an “ emerging growth company ” can take advantage of the extended transition period provided in section 7 ( a ) ( 2 ) ( b ) of the securities act , for complying with new or revised accounting standards . in other words , an “ emerging growth company ” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies . the company has elected to use the extended transition period for complying with new or revised accounting standards under section 102 ( b ) ( 1 ) of the jobs act . this election allows it to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies . as a result of this election , the company 's financial statements may not be comparable to companies that comply with public company effective dates . subject to certain conditions set forth in the jobs act , as an “ emerging growth company , ” the company intends to rely on certain of these exemptions , including without limitation , ( i ) providing an auditor 's attestation report on our system of internal controls over financial reporting pursuant to section 404 ( b ) of the sarbanes-oxley

